top of page
< Back

Paritaprevir


Mechanism of action:

Paritaprevir is an HCV NS3/4A protease inhibitor. The hepatitis C virus polyprotein must be cleaved by the NS3/4A protease into multiple functional proteins, including NS3, NS4A, NS4B, NS5A, and NS5B. Paritaprevir binds with high affinity to the active site of the NS3/4A protease and inhibits its proteolytic activity, preventing the virus from producing mature, functional proteins needed for viral RNA replication and assembly.

Reference(s):

1. Klibanov OM et al. (2015). Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 


2. Hull MW et al. (2016). Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep. 


3. Lam JT et al. (2016). New combination antiviral for the treatment of hepatitis C. Am J Health Syst Pharm.

bottom of page